HUP0101317A2 - Módosított VIII-as faktor - Google Patents

Módosított VIII-as faktor

Info

Publication number
HUP0101317A2
HUP0101317A2 HU0101317A HUP0101317A HUP0101317A2 HU P0101317 A2 HUP0101317 A2 HU P0101317A2 HU 0101317 A HU0101317 A HU 0101317A HU P0101317 A HUP0101317 A HU P0101317A HU P0101317 A2 HUP0101317 A2 HU P0101317A2
Authority
HU
Hungary
Prior art keywords
factor viii
modified factor
subject
amino acid
acid sequences
Prior art date
Application number
HU0101317A
Other languages
English (en)
Inventor
John S. Lollar
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of HUP0101317A2 publication Critical patent/HUP0101317A2/hu
Publication of HUP0101317A3 publication Critical patent/HUP0101317A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

A találmány tárgyát egy hibrid VIII-as faktor képezi, ami tartalmazmind humán mind állati eredetű aminosav szekvenciát, vagy tartalmazhumán VIII-as faktor és nem-VIII-as faktor eredetű aminosavszekvenciát, valamint a találmány tárgyát képezi ezek előállítása éshasználata. Ó
HU0101317A 1998-03-10 1999-03-10 Modified factor viii HUP0101317A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/037,601 US6180371B1 (en) 1996-06-26 1998-03-10 Modified factor VIII
PCT/US1999/005193 WO1999046274A1 (en) 1998-03-10 1999-03-10 Modified factor viii

Publications (2)

Publication Number Publication Date
HUP0101317A2 true HUP0101317A2 (hu) 2001-08-28
HUP0101317A3 HUP0101317A3 (en) 2003-01-28

Family

ID=21895222

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101317A HUP0101317A3 (en) 1998-03-10 1999-03-10 Modified factor viii

Country Status (14)

Country Link
US (1) US6180371B1 (hu)
EP (1) EP1062224A4 (hu)
JP (1) JP2002506076A (hu)
KR (1) KR100490612B1 (hu)
CN (1) CN1224627C (hu)
AU (1) AU747644B2 (hu)
CA (1) CA2322508A1 (hu)
CZ (1) CZ300959B6 (hu)
HU (1) HUP0101317A3 (hu)
IL (1) IL138281A (hu)
NO (1) NO20004497L (hu)
NZ (1) NZ506771A (hu)
PL (1) PL342887A1 (hu)
WO (1) WO1999046274A1 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376463B1 (en) * 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
HUP0301179A3 (en) * 2000-09-19 2006-11-28 Univ Emory Modified factor viii
WO2002060951A2 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
DE60234193D1 (de) * 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
MXPA04001982A (es) * 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
EP1572889B1 (en) * 2001-10-05 2008-12-17 Expression Therapeutics, LLC Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
FR2830865B1 (fr) 2001-10-17 2004-10-22 Centre Nat Rech Scient Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
CN1630666A (zh) * 2001-11-30 2005-06-22 埃默里大学 因子ⅷc2结构域变体
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾されたｖｉｉｉ因子
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ES2449044T3 (es) * 2004-05-03 2014-03-18 Emory University Procedimiento de administración de fVIII sin dominio B porcino
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
US20100256062A1 (en) 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
SG190136A1 (en) 2010-11-05 2013-07-31 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
WO2014089541A2 (en) 2012-12-07 2014-06-12 Haplomics, Inc. Factor viii mutation repair and tolerance induction
US20240010707A1 (en) 2018-04-12 2024-01-11 Biotest Ag De-immunized Factor VIII Molecule and Pharmaceutical Compositions Comprising the Same
CN114391024A (zh) 2019-09-02 2022-04-22 生物测试股份公司 具有增加的半衰期的因子viii蛋白
CN112575034B (zh) * 2019-09-29 2023-04-25 济南赛尔生物科技股份有限公司 一种治疗a型血友病的产品及应用
CN114196677A (zh) * 2021-12-30 2022-03-18 广西医科大学第一附属医院 一种高活性的凝血因子Ⅷ或Ⅷa多肽变体Gly710Ala

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) * 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
US4868112A (en) * 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains

Also Published As

Publication number Publication date
CZ20003282A3 (cs) 2001-01-17
CN1224627C (zh) 2005-10-26
KR100490612B1 (ko) 2005-05-19
JP2002506076A (ja) 2002-02-26
US6180371B1 (en) 2001-01-30
WO1999046274A1 (en) 1999-09-16
IL138281A (en) 2007-06-17
IL138281A0 (en) 2001-10-31
PL342887A1 (en) 2001-07-16
NO20004497L (no) 2000-11-07
AU747644B2 (en) 2002-05-16
CA2322508A1 (en) 1999-09-16
NO20004497D0 (no) 2000-09-08
CZ300959B6 (cs) 2009-09-23
EP1062224A1 (en) 2000-12-27
HUP0101317A3 (en) 2003-01-28
EP1062224A4 (en) 2004-03-03
KR20010082521A (ko) 2001-08-30
AU2995699A (en) 1999-09-27
CN1297452A (zh) 2001-05-30
NZ506771A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
HUP0101317A2 (hu) Módosított VIII-as faktor
DE60233157D1 (de) Zweikammer-herzschrittmacher-system zur diagnose und behebung von arrhythmien
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
HUP0401124A2 (hu) VII koagulációs faktor származékok
ATE333888T1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
HUP0303143A2 (hu) A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása
IL189629A0 (en) Compositions containing human ctla-4 antibodies
EP2158319A4 (en) BONE-TARGETING ALKALINE PHOSPHATASE, KITS AND METHODS FOR USE THEREOF
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
HUP0003852A2 (hu) Erősen szelektív butiril-kolin-észteráz inhibitorok alkalmazása Alzheimer-kór és elmebaj kezelésére és diagnosztizálására
HUP0402396A2 (hu) Aszkomicintartalmú, a szem kezelésére szolgáló készítmények
YU79202A (sh) Peptid koji modulira trombopoetinski receptor
DE69840415D1 (de) Haemasterlin analoge
EP1100815A4 (en) PROTEASE TYPE II CLEAVABLE PEPTIDE
DE60038312D1 (de) Faktor x-analoge mit verbesserter fähigkeit zur aktivierung
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
HK1088016A1 (en) Isolated fluorescent protein from clytia gregaria cgfp and use thereof
AU2002229677A1 (en) Soluble cyclic analogues of beta amyloid peptide
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
TR199900730T2 (xx) S�v� alendronat form�lasyonlar�
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE225805T1 (de) Hundecoronavirus s gen und verwendung davon
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
DE69901243D1 (de) Artikulator zur herstellung von zahnärztlichen prothesen
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal